Page 378 - Basic _ Clinical Pharmacology ( PDFDrive )

364 SECTION IV Drugs with Important Actions on Smooth Muscle

REFERENCES Lee AM, Jacoby DB, Fryer AD: Selective muscarinic receptor antagonists for air-
way diseases. Curr Opin Pharmacol 2001;1:223.
Pathophysiology of Airway Disease Peters SP et al: Tiotropium bromide step-up therapy for adults with uncontrolled
Fahy JV: Type 2 inflammation in asthma: Present in most, absent in many. Nat asthma. N Engl J Med 2010;363:1715.
Rev Immunol 2015;15:57.
Kim HY, DeKruyff RH, Umetsu DT: The many paths to asthma: Phenotype Leukotriene Pathway Inhibitors
shaped by innate and adaptive immunity. Nat Immunol 2010;7:577.
Locksley RM: Asthma and allergic inflammation. Cell 2010;140:777. Calhoun WJ: Anti-leukotrienes for asthma. Curr Opin Pharmacol 2001;1:230.
Lotvall J et al: Asthma endotypes: A new approach to classification of dis- Laidlaw TM et al: Cysteinyl leukotriene overproduction in aspirin-exacerbated respi-
ratory disease is driven by platelet-adherent leukocytes. Blood 2012;119:3790.
ease entities within the asthma syndrome. J Allergy Clin Immunol
2011;127:355. Wang L et al: Cost-effectiveness analysis of fluticasone versus montelukast in
Martinez FD, Vercelli D: Asthma. Lancet 2013;382:1360. children with mild-to-moderate persistent asthma in the Pediatric Asthma
Controller Trial. J Allergy Clin Immunol 2011;127:161.
Asthma Treatment
Anti-IgE Therapy
Bateman ED et al: Overall asthma control: The relationship between current con- Busse WW et al: Randomized trial of omalizumab (anti-IgE) for asthma in inner-
trol and future risk. J Allergy Clin Immunol 2010;125:600. city children. N Engl J Med 2011;364:1005.
Bel EH: Mild asthma. N Engl J Med 2013;369:2362. Walker S et al: Anti-IgE for chronic asthma in adults and children. Cochrane
National Heart, Lung, and Blood Institute, National Asthma Education and Pre- Database Syst Rev 2006;2:CD003559.
vention Program: Expert Panel Report 3: Guidelines for the diagnosis and
management of asthma. National Heart, Lung, and Blood Institute; Revised
August 2007. NIH publication no. 07-4051. https://www.nhlbi.nih.gov/ Targeted Monoclonal Antibody Therapy
health-pro/guidelines/current/asthma-guidelines.
Fainardi V, Pisi G, Chetta A: Mepolizumab in the treatment of severe eosinophilic
asthma. Immunotherapy 2016;8:27.
Beta Agonists Walsh GM: Biologics targeting IL-5, IL-4 or IL-13 for the treatment of asthma: an
update. Expert Rev Clin Immunol 2017;13(2):143.
Ducharme FM et al: Addition of long-acting beta2-agonists to inhaled steroids
versus higher dose inhaled steroids in adults and children with persistent Wenzel S et al: Dupilumab efficacy and safety in adults with uncontrolled persis-
asthma. Cochrane Database Syst Rev 2010;4:CD005533. tent asthma despite use of medium-to-high-dose inhaled corticosteroids plus
Papi A et al: Beclomethasone-formoterol as maintenance and reliever treatment in a long-acting β2 agonist: A randomised double-blind placebo-controlled
pivotal phase 2b dose-ranging trial. Lancet 2016;388:31.
patients with asthma: A double-blind, randomised controlled trial. Lancet
Respir Med 2013;1:23.
Stempel DA et al: Serious asthma events with fluticasone plus salmeterol versus Future Directions of Asthma Therapy
fluticasone alone. N Engl J Med 2016;374:1822. Chang TS et al: Childhood asthma clusters and response to therapy in clinical tri-
Stempel DA et al: Safety of adding salmeterol to fluticasone propionate in children als. J Allergy Clin Immunol 2014;133:363.
with asthma. N Engl J Med 2016;375:840.
Haldar P et al: Cluster analysis and clinical asthma phenotypes. Am J Respir Crit
Care Med 2008;178:218.
Methylxanthines & Roflumilast Lotvall J et al: Asthma endotypes: A new approach to classification of disease
Barnes PJ: Theophylline. Am J Respir Crit Care Med 2013;188:901. entities within the asthma syndrome. J Allergy Clin Immunol 2011;
Rabe KF: Roflumilast for the treatment of chronic obstructive pulmonary disease. 127:355.
Expert Rev Respir Med 2010;4:543. Moore WC et al: Identification of asthma phenotypes using cluster analysis
in the Severe Asthma Research Program. Am J Respir Crit Care Med
2010;181:315.
Cromolyn & Nedocromil
Woodruff PG et al: T-helper type 2-driven inflammation defines major subpheno-
Guevara J et al: Inhaled corticosteroids versus sodium cromoglycate in types of asthma. Am J Respir Crit Care Med 2009;180:388.
children and adults with asthma. Cochrane Database Syst Rev 2006;
2:CD003558.
Management of Acute Asthma
Corticosteroids Lazarus SC: Clinical practice. Emergency treatment of asthma. N Engl J Med
2010;363:755.
Barnes P: How corticosteroids control inflammation: Quintiles Prize Lecture
2005. Br J Pharmacol 2006;148:245. Prospects for Prevention
Beasley R et al: Combination corticosteroid/beta-agonist inhaler as reliever ther-
apy: A solution for intermittent and mild asthma? J Allergy Clin Immunol Klauth M, Heine H: Allergy protection by cowshed bacteria: Recent findings and
2014;133:39. future prospects. Pediatr Allergy Immunol 2016;27:340.
Boushey HA et al: Daily versus as-needed corticosteroids for mild persistent Lynch SV et al: Effects of early-life exposure to allergens and bacteria on recur-
asthma. N Engl J Med 2005;352:1519. rent wheeze and atopy in urban children. J Allergy Clin Immunol 2014;
Suissa S et al: Low-dose inhaled corticosteroids and the prevention of death from 134:593.
asthma. N Engl J Med 2000;343:332. Martinez FD: New insights into the natural history of asthma: Primary prevention
on the horizon. J Allergy Clin Immunol 2011;128:939.
Antimuscarinic Drugs Stein MM et al: Innate immunity and asthma risk in Amish and Hutterite farm
children. N Engl J Med 2016;375:411.
D’Amato M et al: Anticholinergic drugs in asthma therapy. Curr Opin Pulm Med
2016;22:527.